Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia

J Antimicrob Chemother. 2019 Jul 1;74(7):2055-2059. doi: 10.1093/jac/dkz116.

Abstract

Background: Stenotrophomonas maltophilia is intrinsically resistant to several antibiotics, making it potentially challenging to treat. Studies have demonstrated treatment failures and resistance development with monotherapy (MT); however, clinical data are limited with combination therapy (CT).

Objectives: To compare clinical outcomes with CT versus MT for S. maltophilia pneumonia.

Methods: This was a retrospective cohort study of patients admitted between November 2011 and October 2017 with S. maltophilia pneumonia who received at least 48 h of effective therapy. The primary outcome was clinical response after 7 days of effective therapy with CT versus MT. Secondary outcomes included development of a non-susceptible isolate, 30 day microbiological cure, infection recurrence, infection-related mortality and all-cause mortality. The Wilcoxon rank sum test, the Pearson χ2 test and Fisher's exact test were utilized for univariate analyses. A multivariable logistic regression model was used to assess clinical response while adjusting for confounding variables.

Results: Of 252 patients with S. maltophilia pneumonia included, 38 received CT and 214 received MT. There was no difference in 7 day clinical response with CT versus MT (47.4% versus 39.7%, P = 0.38), even after controlling for immune status, APACHE II score and polymicrobial pneumonia (adjusted OR 1.51, 95% CI 0.63-3.65). Thirty day microbiological cure (P = 0.44), recurrence (P = 0.53), infection-related mortality (P = 0.19) and isolation of a non-susceptible isolate during or after therapy (P = 1.00 each) were also similar between both groups; however, 30 day all-cause mortality was greater with CT (P = 0.03).

Conclusions: CT had similar rates of clinical efficacy and resistance development compared with MT for S. maltophilia pneumonia.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Biomarkers
  • Combined Modality Therapy
  • Disease Susceptibility
  • Drug Therapy, Combination
  • Female
  • Gram-Negative Bacterial Infections / diagnosis
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / microbiology*
  • Gram-Negative Bacterial Infections / mortality
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / microbiology*
  • Pneumonia, Bacterial / mortality
  • Prognosis
  • Retrospective Studies
  • Stenotrophomonas maltophilia / drug effects*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Biomarkers